Search results for "HIV infection"

showing 10 items of 314 documents

Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines

2015

CD8 T cells contribute to protective immunity against Mycobacterium tuberculosis. In humans, M. tuberculosis reactive CD8 T cells typically recognize peptides associated to classical MHC class Ia molecules, but little information is available on CD8 T cells recognizing M. tuberculosis Ags presented by nonclassical MHC class Ib molecules. We show here that CD8 T cells from tuberculosis (TB) patients recognize HLA-E-binding M. tuberculosis peptides in a CD3/TCR αβ mediated and CD8-dependent manner, and represent an additional type of effector cells playing a role in immune response to M. tuberculosis during active infection. HLA-E-restricted recognition of M. tuberculosis peptides is detectab…

MaleTetramersCytotoxicHLA-EReceptors Antigen T-Cell alpha-betaT-LymphocytesEpitopes T-LymphocyteHIV InfectionsMycobacterium tuberculosiEpitopesHLA-EReceptorsImmunology and AllergyCells CulturedType 2 cytokinealpha-betaCulturedbiologyCoinfectionType 2 cytokinesMedicine (all)BacterialMiddle AgedAcquired immune systemAntibodies Bacterialmedicine.anatomical_structureTBAntigenCytokinesFemaleNK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily DCD8 T lymphocyteProtein BindingAdultTuberculosisSettore MED/17 - Malattie InfettiveT cellCellsImmunologyAntibodiesMycobacterium tuberculosisImmune systemAntigenMHC class ImedicineHumansTuberculosisAntigensSettore MED/04 - Patologia GeneraleAntigens BacterialCD8 T lymphocytes; HLA-E; Mycobacterium tuberculosis; TB; Tetramers; Type 2 cytokines; Adult; Antibodies Bacterial; Antigens Bacterial; Cells Cultured; Coinfection; Cytokines; Epitopes T-Lymphocyte; Female; HIV Infections; Histocompatibility Antigens Class I; Humans; Male; Middle Aged; Mycobacterium tuberculosis; NK Cell Lectin-Like Receptor Subfamily C; NK Cell Lectin-Like Receptor Subfamily D; Protein Binding; Receptors Antigen T-Cell alpha-beta; T-Lymphocytes Cytotoxic; Tuberculosis; Immunology; Immunology and Allergy; Medicine (all)Histocompatibility Antigens Class IMycobacterium tuberculosismedicine.diseasebiology.organism_classificationT-CellVirologyCD8 T lymphocytesT-LymphocyteImmunologybiology.proteinTetramerT-Lymphocytes CytotoxicCD8 T lymphocytes; HLA-E; Mycobacterium tuberculosis; TB; Tetramers; Type 2 cytokines; Immunology; Immunology and Allergy
researchProduct

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

2012

Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the ma…

MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusiness
researchProduct

Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection.

2013

Background Visceral leishmaniasis is a parasitic disease associated with high mortality. The most important foci of visceral leishmaniasis in Ethiopia are in the Northwest and are predominantly associated with high rates of HIV co-infection. Co-infection of visceral leishmaniasis patients with HIV results in higher mortality, treatment failure and relapse. We have previously shown that arginase, an enzyme associated with immunosuppression, was increased in patients with visceral leishmaniasis and in HIV seropositive patients; further our results showed that high arginase activity is a marker of disease severity. Here, we tested the hypothesis that increased arginase activities associated wi…

MaleViral Diseasesmedicine.medical_treatmentEnzyme MetabolismHIV InfectionsParasite loadBiochemistrySeverity of Illness Index0302 clinical medicineBlood plasmaSUPPRESSOR-CELLSMACROPHAGESPLASMA AMINO-ACIDS0303 health sciencesCoinfectionPARASITOLOGYlcsh:Public aspects of medicineImmunosuppression11 Medical And Health SciencesIMMUNODEFICIENCY-VIRUS TYPE-13. Good healthEnzymesSEROPOSITIVE PATIENTSArginaseInfectious DiseasesCoinfectionMedicineLeishmaniasis VisceralBiological MarkersLife Sciences & BiomedicineResearch ArticleNeglected Tropical DiseasesAdultlcsh:Arctic medicine. Tropical medicineAdolescentlcsh:RC955-962030231 tropical medicineINHIBITIONPeripheral blood mononuclear cellMECHANISMS03 medical and health sciencesYoung AdultDONOVANITropical MedicinemedicineParasitic DiseasesACTIVATED GRANULOCYTESHumansAdolescent; Adult; Arginase/blood; Biological Markers/blood; Coinfection/diagnosis; Coinfection/pathology; Cross-Sectional Studies; Ethiopia; HIV Infections/complications; HIV Infections/diagnosis; Humans; Leishmaniasis Visceral/complications; Leishmaniasis Visceral/diagnosis; Male; Severity of Illness Index; Young AdultBiology030304 developmental biologyScience & TechnologyArginasebusiness.industryPublic Health Environmental and Occupational HealthLeishmaniasislcsh:RA1-127006 Biological Sciencesmedicine.diseaseVisceral leishmaniasisCross-Sectional StudiesImmunologyEthiopiabusinessBiomarkersRESPONSES
researchProduct

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virologica…

Maleadverse eventadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Heterocyclic Compounds 3-Ring; Humans; Italy; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcomeadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity;HIV InfectionsPiperazinesCohort Studies0302 clinical medicineHeterocyclic CompoundsAbacavirRetrospective StudieMedicineHIV InfectionProspective Studies030212 general & internal medicineProspective cohort studyResearch Articlesadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicityHazard ratioMiddle AgedDideoxynucleosidedolutegravirTreatment OutcomeInfectious DiseasesTolerabilityItalyCohortFemalePublic Health0305 other medical scienceHeterocyclic Compounds 3-RingResearch Articlemedicine.drugHumanAdultmedicine.medical_specialtyAnti-HIV AgentsPyridonesantiretroviral therapySettore MED/17 - MALATTIE INFETTIVE3-RingLower riskNO03 medical and health sciencesInternal medicineOxazinescohort studyHumansTenofovirRetrospective Studies030505 public healthbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAnti-HIV AgenttoxicityRetrospective cohort studyantiretroviral therapy; dolutegravir; cohort study; discontinuation; toxicity; adverse eventsDideoxynucleosidesadverse eventsDiscontinuationProspective Studieadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Public Health Environmental and Occupational Health; Infectious DiseasesCohort Studiebusinessdiscontinuation
researchProduct

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

2019

Maleantiretroviral treatmentInfectious Disease TransmissiongenotypeHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeRetrospective StudieGenotypepol Gene Products Human Immunodeficiency ViruPrevalenceMedicineVerticalHIV InfectionViralpol Gene ProductsYoung adultGeneral MedicineInfectious DiseasesItalyMutation (genetic algorithm)FemaleHuman Immunodeficiency VirusHumanMicrobiology (medical)AdultSettore MED/17 - Malattie InfettiveAdolescentAnti-HIV AgentsYoung AdultAcquired resistanceDrug Resistance ViralHumansvertical HIV transmissionAdolescent; Adult; Anti-HIV Agents; Drug Resistance Viral; Female; HIV Infections; HIV-1; Humans; Italy; Male; Mutation; Prevalence; Retrospective Studies; Young Adult; pol Gene Products Human Immunodeficiency Virus; Infectious Disease Transmission VerticalRetrospective StudiesHIV perinatally infectionbusiness.industryAnti-HIV AgentRetrospective cohort studyVirologyInfectious Disease Transmission VerticalLarge cohortpol Gene Products Human Immunodeficiency VirusDrug resistanceMutationHIV-1Drug resistance; HIV-1; antiretroviral treatment; genotype; vertical HIV transmissionbusiness
researchProduct

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit fro…

2009

Objectives: To test retrospectively the ability of four freely available rules-based expert systems to predict short- and medium-term virological outcome following an antiretroviral treatment switch in pre-treated HIV-1 patients. Methods: The HIV-1 genotype interpretation systems (GISs) HIVdb, ANRS, Rega and AntiRetroScan were tested for their accuracy in predicting response to highly active antiretroviral therapy using 8 week (n = 765) and 24 week (n = 634) follow-up standardized treatment change episodes extracted from the Italian Antiretroviral Resistance Cohort Analysis (ARCA) database. A genotypic sensitivity score (GSS) was derived for each genotype-treatment pair for the different GI…

Maleinterpretation systemHIV InfectionsDrug resistanceLogistic regressionRetrospective StudieHIV InfectionPharmacology (medical)Microbial Sensitivity TestMiddle AgedPrognosisgenotype drug resistance algorithmAlgorithmTreatment OutcomeInfectious DiseasesItalyRNA ViralFemaleCohort studyHumanMicrobiology (medical)Adultmedicine.medical_specialtyGenotypeLogistic ModelAnti-HIV AgentsPrognosiantiretroviralMicrobial Sensitivity TestsInternal medicinemedicinePotencyAnimalsHumansRetrospective StudiesPharmacologyReceiver operating characteristicbusiness.industryAnimalAnti-HIV AgentRetrospective cohort studyOdds ratiogenotype; interpretation system; antiretroviral; drug potency weightingWeightingLogistic ModelsROC CurveDrug resistanceImmunologyHIV-1businessdrug potency weighting
researchProduct

Chancre of the eyelid as manifestation of primary syphilis, and precocious chorioretinitis and uveitis in an HIV-infected patient: a case report

2012

Abstract Background Ocular syphilis is often difficult to diagnose because of the wide variation in clinical features. HIV co-infection may further complicate the picture. Case presentation Herein the authors report an unusual primary syphilitic ocular lesion in a 45-year-old Italian HIV-infected bisexual man who presented with a unilateral eyelid lesion. Associated precocious signs and symptoms in the posterior segment of both eyes, bilateral chorioretinitis and uveitis, are described. Intravenous penicillin and steroid treatment produced a rapid improvement in clinical status and complete resolution. Conclusions Careful questioning about sexual behavior is crucial for unmasking unusual fe…

Malemedicine.medical_specialtyAnti-Inflammatory AgentsPrimary SyphilisHIV InfectionsCase ReportPenicillinsOcular syphilislcsh:Infectious and parasitic diseasesUveitisLesionHiv infectedmedicineHumanslcsh:RC109-216HIV-infectedChancre of the eyelidSettore MED/30 - Malattie Apparato Visivobusiness.industryOcular syphilis HIV-infected Chancre of the eyelid Bilateral chorioretinitis UveitisChorioretinitisEyelidsMiddle Agedmedicine.diseaseChancreDermatologyBilateral chorioretinitiseye diseasesSurgeryPosterior segment of eyeballTreatment OutcomeInfectious Diseasesmedicine.anatomical_structureChorioretinitisItalyInjections IntravenousSteroidssense organsEyelidmedicine.symptombusinessUveitisChancreBMC Infectious Diseases
researchProduct

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generati…

2017

Background We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV–HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Methods Patients of the ANRS HC27 BocepreVIH study were genotyped for two ITPA single nucleotide polymorphisms involved in ITPA deficiency. RBV trough concentration (Ctrough) was determined at week (W)4 and W8. Impact of ITPA deficiency on anaemia, RBV Ctrough, response and haematotoxicity (grade 3/4 anaemia, erythropoietin [EPO] use, RBV dose reduction or transfusion between day [D]0 and W8) was evaluated. Impact of RBV Ctrough on anaemia…

Malemedicine.medical_specialtyGenotype[SDV]Life Sciences [q-bio]Human immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeAntiviral AgentsGastroenterologychemistry.chemical_compoundPharmacotherapyGene FrequencyRisk FactorsInternal medicineRibavirinmedicineHumansGenetic Predisposition to DiseasePharmacology (medical)PyrophosphatasesAllelesComputingMilieux_MISCELLANEOUSPharmacologyCoinfectionbusiness.industryRibavirinAnemiaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFirst generation3. Good health[SDV] Life Sciences [q-bio]Infectious DiseaseschemistryMutationCoinfectionDrug Therapy CombinationFemaleITPAbusinessMetabolism Inborn ErrorsINOSINE TRIPHOSPHATASE
researchProduct

Time trends, characteristics, and evidence of scientific advances within the legal complaints for alleged sexual HIV transmission in Spain: 1996-2012.

2014

This article quantifies and characterizes existing legal complaints for the sexual transmission of HIV in Spain, describes temporal trends and whether advance of scientific knowledge is reflected in charging decisions, judicial reasoning, and sentences. Sentences and writs dictated by Spanish penal and civil jurisdictions between 1981 and 2012 were obtained through legal databases systematic search. Sixteen sentences and 9 writs belonging to 19 cases were included; 17 judged by penal and two by civil jurisdictions. The first sentence was pronounced in 1996, 3 between 1999 and 2000, 4 between 2001 and 2005, and 18 between 2006 and 2012. In 10 (53%) cases there was effective HIV transmission,…

Malemedicine.medical_specialtyHealth Knowledge Attitudes PracticeHealth (social science)Sexual transmissionSocial PsychologySexual BehaviorHIV InfectionsMen who have sex with menCondomsCriminalizationmedicineHumansHiv transmissionPsychiatrySubstance Abuse IntravenousHealth policyCrime VictimsPlaintiffSocial Responsibilitybusiness.industryPublic Health Environmental and Occupational HealthJudicial opinionSexual PartnersSpainFemalebusinessSocial psychologySentenceAIDS care
researchProduct

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort

2017

International audience; Background & aims: There is little data available on the use of new oral direct-acting antiviral (DAA) regimens to treat human immunodeficiency virus and hepatitis C virus (HIV/HCV) co-infected patients in real-life settings. Here, the efficacy and safety of all-oral DAA-based regimens in HIV/HCV-co-infected patients enrolled in the French nationwide ANRS CO13 HEPAVIH observational cohort are reported.Methods: HIV/HCV-co-infected patients enrolled in the ANRS CO13 HEPAVIH observational cohort were included if they began an all-oral DAA-based regimen before 1st May 2015 (12-week regimens) or 1st February 2015 (24-week regimens). Treatment success (SVR12) was defined b…

Malemedicine.medical_specialtyHepatitis C virus[SDV]Life Sciences [q-bio]Integrase inhibitorHIV Infectionsmedicine.disease_causeAntiviral AgentsHIV/HCV co-infectionCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineparasitic diseasesmedicineHumans030212 general & internal medicineAdverse effectHepatologyReverse-transcriptase inhibitorbusiness.industryCoinfectionRibavirinvirus diseasesHepatitis C ChronicMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthRegimenSustained virological responseLogistic ModelschemistryImmunologyCohort030211 gastroenterology & hepatologyFemaleAll-oral DAAbusinessCohort studymedicine.drug
researchProduct